Thyroid hormones are known to be potent modulators of hepatic metabolism and targeting the thyroid hormone receptor was recently approved as the first treatment for metabolic-associated steatotic liver disease (MASLD); however, the exact relationship between thyroid disorders and biopsy-confirmed MASLD remains unclear. The gene discussed is TG; the disease is thyroid gland disorder.